RNA manufacturing has come a long way, fast. But talk to the people working in the lab and on the manufacturing floor, and the same questions keep coming up:
- Are we measuring the right quality attributes?
- Do our analytical methods actually predict how an RNA will perform biologically?
- How can we understand our process earlier, before problems get expensive?
- What would it take to simplify RNA manufacturing and QC, and speed up scale-up?
We put those questions to three experts from academia, applied research and industry, and let the conversation run. The result is a candid look at where RNA analytics and manufacturing stand today, and where they need to go next.
The series
We've split the discussion into three episodes, so you can start with the topic that matters most to you.
Episode 1: From RNA quality to biological function
Are we measuring the right things? The panel looks at why it's still hard to link quality attributes to biological performance, and where today's QC workflows fall short, including assay standardization, analytical sensitivity and structural characterization.
Episode 2: Capping efficiency and residual template DNA
A closer look at two critical control points. The panel covers best practices and common challenges in monitoring them, and how moving critical analytics upstream could improve process understanding, reduce costs and accelerate development.
COMING SOON - Monday 19th October
Episode 3: The future of RNA manufacturing
Where do the experts think the field is heading? Topics include integrated QC platforms, advanced analytics, improved enzymes and next-generation process controls.
COMING SOON - Wednesday 21th October
Get notefied when each episode drops?
Follow us on LinkedIn to stay up to date with the latest releases.
Meet the panel
Mark Dickman
Professor of Biosciences and Engineering, University of Sheffield
Nucleic acid analytics expert who works with advanced characterization technologies, including HPLC and mass spectrometry, for RNA therapeutics and mRNA products.
Francis Combes
Senior Research Scientist, SINTEF
Researcher working across RNA therapeutics, RNA quality assessment, process development, nucleic acid characterization and next-generation vaccine technologies.
Ashish Dhir
Director of RNA, 4BaseBio
Leads RNA strategy and development, advancing synthetic DNA and RNA technologies for next-generation therapeutics, vaccines and gene therapies.
Stephen Dey
Director of Product Management & Marketing, ArcticZymes Technologies.
